Cath Lab

The cardiac catheterization laboratory is used for diagnostic angiograms and percutaneous coronary interventions (PCI). Cath labs have also seen expanding use in recent years for transcatheter structural heart procedures. Some hospitals also share these labs with other subspecialties for catheter-based procedures in electrophysiology (EP), interventional radiology, peripheral artery disease (PAD), carotid and neuro interventional procedures and vascular surgery.

RSS icon
he U.S. Food and Drug Administration (FDA) granted market clearance ion September 2022 for the Edwards Lifesciences Corp. Pascal Precision transcatheter valve repair system for transcatheter edge-to-edge repair (TEER). It is indicated for the treatment of patients with degenerative mitral regurgitation (DMR).

FDA clears Edwards Pascal device for transcatheter mitral valve repair

This is the second FDA-cleared transcatheter repair device for the mitral valve. Data from pivotal trial comparing Pascal vs. MitraClip will be presented at TCT 2022.

A structural heart Presentation during the TVT 2022 conference. #TCT #TCT22 #TCT2022

TCT 2022 late-breaking clinical presentations announced

The Cardiovascular Research Foundation (CRF) announced the 32 late-breaking studies being presented at the Transcatheter Cardiovascular Therapeutics 2022 annual meeting at in Boston, Sept. 16-19.

Thumbnail

HFpEF patients with MR may face a higher mortality risk—but not if they have AFib

There is an established connection between MR and HFrEF, but we know much less about the link between MR and HFpEF. 

Three transcatheter tricuspid valve repair and replacement (TTVR) technologies that will likely see FDA clearance in. the next couple years include the Edwards Evoque transcatheter tricuspid valve (top left), Abbott TriClip (below) and the Edwards Lifesciences Pascal clip device (right).

Tricuspid valve therapies moving ahead of mitral therapies seeking market approval

The complexity of the mitral valve has slowed development of new transcatheter technologies, and it now seems much more likely that transcatheter devices for tricuspid valve will push ahead to gain FDA clearances.

Interview with Rebecca T. Hahn, MD, Professor of Medicine at Columbia University Irving Medical Center, Chief Scientific Officer of the Echo Core Lab at the Cardiovascular Research Foundation and Director of Interventional Echocardiography at the Columbia Structural Heart and Valve Center. She discusses some of the trends of growing use of interventional echocardiographic guidance in transcatheter structural heart procedures, the growing number of tricuspid valve procedures, and use of 3D ICE.

VIDEO: Trends in structural heart procedural imaging - a discussion with Rebecca Hahn

Rebecca T. Hahn, MD, Director of Interventional Echocardiography at the Columbia Structural Heart and Valve Center, discusses some of the trends in the growing use of interventional echocardiographic guidance in transcatheter structural heart procedures.

FDA warns of a new malfunction risk with Abbott’s MitraClip devices

When these malfunctions occur, the FDA explained, it leads to an increased risk of additional interventions.

DOACs after TAVR may put some patients at risk, new meta-analysis suggests

The new study, based on data from nearly 3,000 patients, compared DOACs such as rivaroxaban, apixaban and edoxaban with single and dual antiplatelet therapy. 

SAVR after TAVR is rare, but linked to a high mortality risk

Researchers tracked data from more than 2,000 patients, noting that surgical bailout, infective endocarditis and paravalvular leak were the most common reasons for surgery to be required after TAVR. The full study was published in the American Journal of Cardiology.

Displaying 241 - 248 of 569

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.